Key facts
- Smart Tissues’s last known valuation is $4.0M (Aug 2020).
- It has raised $360K; the latest was Seed Round ($160K) in Jan 2025.
- Notable investors include Antler, Start-Up Chile, Beyond Japan, Institute for the Global Entrepreneur, Medtech Actuator — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Smart Tissues
- ·The full record, as it builds
Funding rounds
No funding rounds for Smart Tissues are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Smart Tissues
Developer of bioprinting technologies intended to offer researchers access to the tools for printing realistic human-like tissues. The company offers innovative bionics that allow human cells to grow and proliferate as they would in the human body environment, enabling investigators to use 3D models to better understand how organisms develop in normal and disease conditions.
- Sector
- Healthcare
- HQ
- Kyoto, Japan
- Founded
- 2020
- Employees
- 6
- Website
- smart-tissues.com/
- Ownership
- Privately Held (backing)
Smart Tissues doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Smart Tissues shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Smart Tissues in its N-PORT filings yet. We sweep new filings monthly.